Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference newsletter

  Ovarian Neoplasms

  Free Subscription

Articles published in Tumour Biol

Retrieve available abstracts of 62 articles:
HTML format

Single Articles

    May 2020
  1. ALVES MC, Fonseca FLA, Yamada AMTD, Barros LADR, et al
    Increased circulating tumor DNA as a noninvasive biomarker of early treatment response in patients with metastatic ovarian carcinoma: A pilot study.
    Tumour Biol. 2020;42:1010428320919198.
    PubMed     Abstract available

    April 2019
  2. OUH YT, Cho HW, Lee JK, Choi SH, et al
    CXC chemokine ligand 1 mediates adiponectin-induced angiogenesis in ovarian cancer.
    Tumour Biol. 2019;42:1010428319842699.
    PubMed     Abstract available

    January 2019
  3. RAMALHO S, Andrade LAA, Filho CC, Natal RA, et al
    Role of discoidin domain receptor 2 (DDR2) and microRNA-182 in survival of women with high-grade serous ovarian cancer.
    Tumour Biol. 2019;41:1010428318823988.
    PubMed     Abstract available

    October 2018
  4. OKLA K, Surowka J, Fraszczak K, Czerwonka A, et al
    Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
    Tumour Biol. 2018;40:1010428318804937.
    PubMed     Abstract available

    June 2018
  5. SADLECKI P, Jozwicki J, Antosik P, Grabiec M, et al
    Expression of selected epithelial-mesenchymal transition transcription factors in serous borderline ovarian tumors and type I ovarian cancers.
    Tumour Biol. 2018;40:1010428318784807.
    PubMed     Abstract available

    May 2018
  6. JAGADISH N, Fatima R, Sharma A, Devi S, et al
    Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
    Tumour Biol. 2018;40:1010428318773652.
    PubMed     Abstract available

    October 2017
  7. SADLECKI P, Antosik P, Grzanka D, Grabiec M, et al
    KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system.
    Tumour Biol. 2017;39:1010428317733984.
    PubMed     Abstract available

    September 2017
  8. SHI C, Qin L, Gao H, Gu L, et al
    NUCKS nuclear elevated expression indicates progression and prognosis of ovarian cancer.
    Tumour Biol. 2017;39:1010428317714631.
    PubMed     Abstract available

  9. MARQUES DS, Grativol J, Alves da Silva Peres R, da Rocha Matos A, et al
    Osteopontin-c isoform levels are associated with SR and hnRNP differential expression in ovarian cancer cell lines.
    Tumour Biol. 2017;39:1010428317725442.
    PubMed     Abstract available

    July 2017
  10. CHEN H, Deng Z, Huang C, Wu H, et al
    Mass spectrometric profiling reveals association of N-glycan patterns with epithelial ovarian cancer progression.
    Tumour Biol. 2017;39:1010428317716249.
    PubMed     Abstract available

  11. ZHU L, Feng H, Jin S, Tan M, et al
    High expressions of BCL6 and Lewis y antigen are correlated with high tumor burden and poor prognosis in epithelial ovarian cancer.
    Tumour Biol. 2017;39:1010428317711655.
    PubMed     Abstract available

  12. YU J, Han Q, Cui Y
    Decreased long non-coding RNA SPRY4-IT1 contributes to ovarian cancer cell metastasis partly via affecting epithelial-mesenchymal transition.
    Tumour Biol. 2017;39:1010428317709129.
    PubMed     Abstract available

  13. ZHANG J, Jiang Y, Zhao Y, Wang W, et al
    Downregulation of tyrosine threonine kinase inhibits tumor growth via G2/M arrest in human endometrioid endometrial adenocarcinoma.
    Tumour Biol. 2017;39:1010428317712444.
    PubMed     Abstract available

  14. SUN Y, Fan X, Zhang Q, Shi X, et al
    Cancer-associated fibroblasts secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1/FGFR4 signaling.
    Tumour Biol. 2017;39:1010428317712592.
    PubMed     Abstract available

    June 2017
  15. CHANG L, Guo R, Yuan Z
    IL-36alpha suppresses proliferation of ovarian cancer cells.
    Tumour Biol. 2017;39:1010428317706918.
    PubMed     Abstract available

  16. LI Q, Xue X, Li W, Wang Q, et al
    Heterogeneous DNA methylation status in same-cell subpopulations of ovarian cancer tissues.
    Tumour Biol. 2017;39:1010428317701650.
    PubMed     Abstract available

  17. SUN H, Shi JX, Zhang HF, Xing MT, et al
    Serum autoantibodies against a panel of 15 tumor-associated antigens in the detection of ovarian cancer.
    Tumour Biol. 2017;39:1010428317699132.
    PubMed     Abstract available

  18. HUANG L, Zhou Y, Cao XP, Lin JX, et al
    KPNA2 is a potential diagnostic serum biomarker for epithelial ovarian cancer and correlates with poor prognosis.
    Tumour Biol. 2017;39:1010428317706289.
    PubMed     Abstract available

  19. PING H, Guo L, Xi J, Wang D, et al
    Angiotensin II type 2 receptor-interacting protein 3a inhibits ovarian carcinoma metastasis via the extracellular HMGA2-mediated ERK/EMT pathway.
    Tumour Biol. 2017;39:1010428317713389.
    PubMed     Abstract available

  20. WANG J, Liu Q, Zhou X, He Y, et al
    Thymidine kinase 1 expression in ovarian serous adenocarcinoma is superior to Ki-67: A new prognostic biomarker.
    Tumour Biol. 2017;39:1010428317706479.
    PubMed     Abstract available

    May 2017
  21. LIU T, Zhao L, Hou H, Ding L, et al
    Ginsenoside 20(S)-Rg3 suppresses ovarian cancer migration via hypoxia-inducible factor 1 alpha and nuclear factor-kappa B signals.
    Tumour Biol. 2017;39:1010428317692225.
    PubMed     Abstract available

  22. WANG LL, Xiu YL, Chen X, Sun KX, et al
    The transcription factor FOXA1 induces epithelial ovarian cancer tumorigenesis and progression.
    Tumour Biol. 2017;39:1010428317706210.
    PubMed     Abstract available

  23. KOO YJ, Kim TJ, Min KJ, So KA, et al
    CXCL11 mediates TWIST1-induced angiogenesis in epithelial ovarian cancer.
    Tumour Biol. 2017;39:1010428317706226.
    PubMed     Abstract available

  24. XU Y, Ma YH, Pang YX, Zhao Z, et al
    Ectopic repression of receptor tyrosine kinase-like orphan receptor 2 inhibits malignant transformation of ovarian cancer cells by reversing epithelial-mesenchymal transition.
    Tumour Biol. 2017;39:1010428317701627.
    PubMed     Abstract available

  25. LI Y, Xiao M, Guo F
    The role of Sox6 and Netrin-1 in ovarian cancer cell growth, invasiveness, and angiogenesis.
    Tumour Biol. 2017;39:1010428317705508.
    PubMed     Abstract available

  26. SU YK, Huang WC, Lee WH, Bamodu OA, et al
    Methoxyphenyl chalcone sensitizes aggressive epithelial cancer to cisplatin through apoptosis induction and cancer stem cell eradication.
    Tumour Biol. 2017;39:1010428317691689.
    PubMed     Abstract available

  27. GASPARRI ML, Casorelli A, Bardhi E, Besharat AR, et al
    Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer.
    Tumour Biol. 2017;39:1010428317695525.
    PubMed     Abstract available

  28. SADLECKI P, Walentowicz P, Bodnar M, Marszalek A, et al
    Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.
    Tumour Biol. 2017;39:1010428317706230.
    PubMed     Abstract available

    March 2017
  29. CHENG J, Su M, Jin Y, Xi Q, et al
    Upregulation of SENP3/SMT3IP1 promotes epithelial ovarian cancer progression and forecasts poor prognosis.
    Tumour Biol. 2017;39:1010428317694543.
    PubMed     Abstract available

  30. WANG D, Cao X, Zhang Y, Liu Y, et al
    LAMP3 expression correlated with poor clinical outcome in human ovarian cancer.
    Tumour Biol. 2017;39:1010428317695014.
    PubMed     Abstract available

  31. DU Z, Sha X
    Demethoxycurcumin inhibited human epithelia ovarian cancer cells' growth via up-regulating miR-551a.
    Tumour Biol. 2017;39:1010428317694302.
    PubMed     Abstract available

    February 2017
  32. VALLIUS T, Hynninen J, Auranen A, Matomaki J, et al
    Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
    Tumour Biol. 2017;39:1010428317691189.
    PubMed     Abstract available

  33. DAROOEI M, Poornima S, Salma BU, Iyer GR, et al
    Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population.
    Tumour Biol. 2017;39:1010428317694303.
    PubMed     Abstract available

  34. MA L, Zhang W, Ding Z, Wu SG, et al
    Association of a common variant of SYNPO2 gene with increased risk of serous epithelial ovarian cancer.
    Tumour Biol. 2017;39:1010428317691185.
    PubMed     Abstract available

    November 2016
  35. AZIZMOHAMMADI S, Safari A, Seifoleslami M, Rabati RG, et al
    Retraction Note to: Clinical significance and expression of the PRSS3 and Wiskott-Aldrich syndrome protein family verprolin-homologous protein 1 for the early detection of epithelial ovarian cancer.
    Tumour Biol. 2016.

  36. LIN L, Wang Z, Jin H, Shi H, et al
    MiR-212/132 is epigenetically downregulated by SOX4/EZH2-H3K27me3 feedback loop in ovarian cancer cells.
    Tumour Biol. 2016.
    PubMed     Abstract available

    October 2016
  37. HOU R, Jiang L, Yang Z, Wang S, et al
    Rab14 is overexpressed in ovarian cancers and promotes ovarian cancer proliferation through Wnt pathway.
    Tumour Biol. 2016.
    PubMed     Abstract available

  38. ZHANG W, Yang J, Cao D, You Y, et al
    Regulation of exosomes released from normal ovarian epithelial cells and ovarian cancer cells.
    Tumour Biol. 2016.
    PubMed     Abstract available

  39. HADA M, Subramanian C, Andrews PC, Kwok RP, et al
    Cytosolic Ku70 regulates Bax-mediated cell death.
    Tumour Biol. 2016;37:13903-13914.
    PubMed     Abstract available

    September 2016
  40. XIAOHONG Z, Lichun F, Na X, Kejian Z, et al
    MiR-203 promotes the growth and migration of ovarian cancer cells by enhancing glycolytic pathway.
    Tumour Biol. 2016.
    PubMed     Abstract available

  41. SHEN Y, Li L
    Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Tumour Biol. 2016.
    PubMed     Abstract available

  42. MO Q, Zhang Y, Jin X, Gao Y, et al
    Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis.
    Tumour Biol. 2016.
    PubMed     Abstract available

  43. WATROWSKI R, Heinze G, Jager C, Forster J, et al
    Usefulness of the preoperative platelet count in the diagnosis of adnexal tumors.
    Tumour Biol. 2016;37:12079-12087.
    PubMed     Abstract available

  44. FARKKILA A, Zauli G, Haltia UM, Pihlajoki M, et al
    Circulating levels of TNF-related apoptosis inducing-ligand are decreased in patients with large adult-type granulosa cell tumors-implications for therapeutic potential.
    Tumour Biol. 2016;37:11909-11916.
    PubMed     Abstract available

  45. GAO S, Zhu L, Feng H, Hu Z, et al
    Gene expression profile analysis in response to alpha1,2-fucosyl transferase (FUT1) gene transfection in epithelial ovarian carcinoma cells.
    Tumour Biol. 2016;37:12251-12262.
    PubMed     Abstract available

    August 2016
  46. LU H, Liu Y, Wang D, Wang L, et al
    Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-kappaB pathway.
    Tumour Biol. 2016;37:11469-77.
    PubMed     Abstract available

  47. GANSMO LB, Bjornslett M, Halle MK, Salvesen HB, et al
    The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer.
    Tumour Biol. 2016;37:10697-702.
    PubMed     Abstract available

    July 2016
  48. CHUDECKA-GLAZ A, Cymbaluk-Ploska A, Jastrzebska J, Menkiszak J, et al
    Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status?
    Tumour Biol. 2016;37:8879-87.
    PubMed     Abstract available

    June 2016
  49. LI N, Zhao X, Wang L, Zhang S, et al
    miR-494 suppresses tumor growth of epithelial ovarian carcinoma by targeting IGF1R.
    Tumour Biol. 2016;37:7767-76.
    PubMed     Abstract available

    May 2016
  50. ZHANG W, Niu C, He W, Hou T, et al
    Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
    Tumour Biol. 2016;37:6239-54.
    PubMed     Abstract available

    April 2016
  51. SHI C, Zhang Z
    miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma.
    Tumour Biol. 2016;37:5437-43.
    PubMed     Abstract available

  52. WATROWSKI R, Zeillinger R
    Simple laboratory score improves the preoperative diagnosis of adnexal mass.
    Tumour Biol. 2016;37:4343-9.
    PubMed     Abstract available

  53. HASBY EA
    Mammary serine protease inhibitor and CD138 immunohistochemical expression in ovarian serous and clear cell carcinomas.
    Tumour Biol. 2016;37:4889-900.
    PubMed     Abstract available

  54. LOPES-COELHO F, Gouveia-Fernandes S, Goncalves LG, Nunes C, et al
    HNF1beta drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC).
    Tumour Biol. 2016;37:4813-29.
    PubMed     Abstract available

    March 2016
  55. ZHAN L, Zhang Y, Wang W, Song E, et al
    E2F1: a promising regulator in ovarian carcinoma.
    Tumour Biol. 2016;37:2823-31.
    PubMed     Abstract available

  56. BU M, Shen Y, Seeger WL, An S, et al
    Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8(+) T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression.
    Tumour Biol. 2016;37:3949-56.
    PubMed     Abstract available

  57. SHEN DF, Liu X, Yang XF, Fang L, et al
    The roles of parafibromin expression in ovarian epithelial carcinomas: a marker for differentiation and prognosis and a target for gene therapy.
    Tumour Biol. 2016;37:2909-24.
    PubMed     Abstract available

  58. MOMENY M, Ghasemi R, Valenti G, Miranda M, et al
    Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway.
    Tumour Biol. 2016;37:3913-23.
    PubMed     Abstract available

  59. EL-GENDI S, Abdelzaher E, Mostafa MF, Sheasha GA, et al
    FGF18 as a potential biomarker in serous and mucinous ovarian tumors.
    Tumour Biol. 2016;37:3173-83.
    PubMed     Abstract available

    February 2016
  60. ZHANG P, Wang C, Cheng L, Zhang P, et al
    Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women.
    Tumour Biol. 2016;37:2183-91.
    PubMed     Abstract available

    January 2016
  61. BHASKARI J, Premalata CS, Shilpa V, Rahul B, et al
    Vascular endothelial growth factor polymorphisms and a synchronized examination of plasma and tissue expression in epithelial ovarian cancers.
    Tumour Biol. 2016;37:1017-23.
    PubMed     Abstract available

  62. YAN J, Zhang Y, Shi W, Ren C, et al
    The critical role of HMGA2 in regulation of EMT in epithelial ovarian carcinomas.
    Tumour Biol. 2016;37:823-8.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.